Mercados españoles cerrados

Codexis, Inc. (CDXS)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
3,4400-0,2700 (-7,28%)
A partir del 12:40PM EDT. Mercado abierto.

Codexis, Inc.

200 Penobscot Drive
Redwood City, CA 94063
United States
650 421 8100
https://www.codexis.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo174

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Dr. Stephen George Dilly MBBS, Ph.D.President, CEO & Director1,88MN/A1960
Mr. Sriram Ryali M.B.A.Chief Financial Officer770,45kN/A1981
Mr. Kevin Norrett M.B.A., M.S.Chief Operating Officer739,56kN/A1973
Carrie McKimDirector of Investor RelationsN/AN/AN/A
Ms. Margaret Nell Fitzgerald J.D.Chief Legal & Compliance Officer, General Counsel and Secretary300,03kN/A1971
Ms. Karen Frechou-ArmijoSenior VP & Head of Human ResourcesN/AN/AN/A
Dr. Stefan Lutz Ph.D.Senior Vice President of ResearchN/AN/AN/A
Mr. Robert Sato M.B.A., Ph.D.Senior Vice President of Pharmaceutical Development, Quality & RegulatoryN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Gobierno corporativo

El ISS Governance QualityScore de Codexis, Inc., a día 1 de julio de 2024, es 6. Las puntuaciones base son Auditoría: 3; Tablero: 3; Derechos de los accionistas: 8; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.